As part of its collaboration with the National Institutes of Health (NIH) in the DNA vaccine clinical trial for the Zika virus, PharmaJet is providing its Stratis Needle-Free device and training to the NIH.
Inovio Pharmaceuticals and GeneOne Life Science have dosed the first patient in the multi-center, phase I clinical trial of the companies’ Zika vaccine.
Replikins’ genomic understanding of the Zika and Flaviviruses has led to the development of a trivalent vaccine for Zika, Dengue, and Japanese Encephalitis.
Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
Ennaid Therapeutics has announced it is developing therapeutic cures to help those that may become infected with the Zika Virus, and it may be available in less than four years.
Zika researchers are using animal models and epidemiological studies to try and determine if the virus causes birth defects and neurological disorders.
Sanofi Pasteur has launched a Zika vaccine project, levering its experience in developing vaccines for similar viruses, as the US government pushes for “intensified research.”
